ReviewMarine drugs2026
Brown Seaweed Phlorotannins: Chemical Diversity, Sustainable Extraction, Selective Quantification, Ageing-Related Bioactivities, and Phlorotannin-First Biorefinery Potential.
Review in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Phlorotannins are the characteristic phenolic metabolites of brown seaweeds and represent one of the most chemically diverse, analytically challenging, and industrially promising classes of marine polyphenols. Unlike terrestrial phenolics, phlorotannins are formed from phloroglucinol units and occur as complex mixtures of fucols, phlorethols, fuhalols, fucophlorethols, eckols, and related oligomeric or polymeric structures whose composition varies strongly with species, tissue, season, habitat, extraction protocol, and purification strategy. This review critically examines brown seaweed phlorotannins across five major dimensions: chemical diversity and species-dependent availability; extraction, enrichment, and sustainable solvent strategies, including natural deep eutectic solvents (NADES); analytical challenges and advances in selective quantification, highlighting the non-specific nature of Folin-Ciocalteu assays and the emerging value of selective qNMR-based quantification; and biological relevance to ageing-associated processes such as oxidative stress, inflammation, glycation, metabolic dysfunction, neurodegeneration, and skin ageing. The review further evaluates translational barriers, including poor standardization, uncertain bioavailability, matrix interference, limited compound-specific standards, and insufficient in vivo and clinical validation. Finally, a phlorotannin-first brown seaweed biorefinery framework is proposed, in which the phenolic fraction is recovered early as a high-value stream before sequential valorization of polysaccharides, proteins, pigments, minerals, and residual biomass. This integrated perspective highlights the need to move from crude "total phenolic" descriptions toward chemically defined, functionally validated, and industrially scalable phlorotannin systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.